Related Experiment Video
Updated: Jul 19, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?
Karmele Valencia1,2,3,4,5, Luis M Montuenga1,2,3,5,6, Alfonso Calvo1,2,3,5,6
1Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
Abstract:
The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.
Related Concept Videos
Tumor Immunotherapy
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
lncRNA - Long Non-coding RNAs

